Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?

Ayesha Shah,Gerald Holtmann

DOI: https://doi.org/10.1111/apt.17990

IF: 9.524

2024-04-25

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 10, Page 1290-1291, May 2024.

pharmacology & pharmacy,gastroenterology & hepatology

What problem does this paper attempt to address?

An 'Adaptive Treatment Strategy' for Oral Vancomycin in Patients with the Orphan Disease Primary Sclerosing Cholangitis

Ayesha Shah,James Tabibian,Cynthia Buness,Gerald J. Holtmann

DOI: https://doi.org/10.1007/s10620-024-08497-4

2024-06-21

Digestive Diseases and Sciences

Abstract:Decision-making in clinical medicine ideally is based upon evidence from randomized, placebo-controlled trials (RCTs) and subsequent systematic reviews and meta-analyses. However, for orphan diseases, the expectation of having one or multiple RCTs that inform clinical guidelines or justify specific treatments can be unrealistic and subsequent therapeutic nihilism can be detrimental to patients. This article discusses the benefits of therapeutic decision-making in the context of orphan diseases, focusing on primary sclerosing cholangitis (PSC) as an example of an orphan disease with poor clinical outcomes. PSC is a rare disorder characterized by inflammation and progressive fibrosis of the bile ducts. It carries a high risk of liver failure, malignancies, and debilitating symptoms that impair quality of life. Liver transplantation is currently the only life-prolonging intervention for PSC, but it is not a curative option. The article highlights the potential benefits of treating PSC patients with oral vancomycin (OV), which has shown significant clinical responses and improved quality of life in some cases. However, access to OV therapy is limited due to the lack of RCTs supporting its use. The standard requirement of having evidence from RCTs may result in withholding potentially life-altering and/or life-saving treatments for patients with orphan diseases. Conducting RCTs is challenging in these patient populations due to difficulties in recruiting the required patient cohorts and limited commercial returns. A standardized 'adaptive treatment strategy' is proposed to address this. This approach leverages the best available evidence for specific treatments, considers individual clinical responses, and adjusts treatment over time.

gastroenterology & hepatology
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium

Amanda Ricciuto,Kuan Liu,Wael El‐Matary,Mansi Amin,Achiya Z. Amir,Madeleine Aumar,Marcus Auth,Matthew D. Di Guglielmo,Eleonora Druve Tavares Fagundes,Alexandre Rodrigues Ferreira,Katryn N. Furuya,Nitika Gupta,Stephen Guthery,Simon P. Horslen,Kyle Jensen,Binita M. Kamath,Nanda Kerkar,B. G. P. Koot,Trevor J. Laborda,Christine K. Lee,Kathleen M. Loomes,Cara Mack,Mercedes Martinez,Aldo Montano‐Loza,Nadia Ovchinsky,Alexandra Papadopoulou,Emily R. Perito,Pushpa Sathya,Kathleen B. Schwarz,Uzma Shah,Eyal Shteyer,Nisreen Soufi,James Patrick Stevens,Amy Taylor,M. Elizabeth Tessier,Pamela Valentino,Marek Woynarowski,Mark Deneau,the Pediatric PSC Consortium,Matthew D. Di Guglielmo,Eleonora Druve Tavares Fagundes,Alexandre Rodrigues Ferreira,Binita M. Kamath,Christine K. Lee,Emily R. Perito,M. Elizabeth Tessier

DOI: https://doi.org/10.1111/apt.17936

IF: 9.524

2024-03-12

Alimentary Pharmacology & Therapeutics

Abstract:Results of matched analysis of vancomycin‐treated and untreated children with PSC‐IBD from the Pediatric PSC Consortium, showing higher rates of clinical remission (unadjusted and adjusted for covariates including other medication exposure; in UC and CD) and endoscopic remission in the subset with endoscopic data available. Summary Background Data on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited. Aims Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. Methods In this retrospective multi‐centre cohort study, we matched vancomycin‐treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE. Results 113 PSC‐IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin‐treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97–6.31; adjusted OR [aOR] 5.24, 95% CI 2.68–10.22). Benefit was maintained in sensitivity analyses restricted to non‐transplanted patients and those with baseline moderate–severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002–7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p

pharmacology & pharmacy,gastroenterology & hepatology
Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon

D. Bogatic,R. V. Bryant

DOI: https://doi.org/10.1111/apt.18098

IF: 9.524

2024-07-18

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Bogatic et al papers. To view these articles, visit https://doi.org/10.1111/apt.17251 and https://doi.org/10.1111/apt.17936

pharmacology & pharmacy,gastroenterology & hepatology
A100 ORAL VANCOMYCIN THERAPY FOR CLOSTRIDIOIDES DIFFICILE INFECTION AND RISK OF INFECTION WITH GRAM-NEGATIVE ORGANISMS

A Someili,A Alosail,A Brooks,N Irfan,D Leto,A Hadzic,A Alajmi,D Mertz,M Bader

DOI: https://doi.org/10.1093/jcag/gwz047.099

2020-02-01

Journal of the Canadian Association of Gastroenterology

Abstract:Abstract Background Vancomycin is the recommended first-line therapy for mild to severe Clostridioides difficile infection (CDI). However, oral vancomycin is associated with disruption of the indigenous microbiota, predisposing patients to overgrowth of endogenous pathogens such as vancomycin-resistant enterococci. Aims The primary objective of the study is to examine the effect of the treatment regimens of CDI on the risk of infection with gram-negative organisms in adult patients treated for CDI. Methods A retrospective cohort study of 319 adult patients treated for CDI at Hamilton Health Sciences in the year 2015. A multivariate logistic regression analysis was performed to determine if oral vancomycin-based therapy is associated with an increased risk of infection with gram-negative organisms after adjustment for other factors. Results Eighty-one patients were excluded because of recurrent episodes of CDI within the same year or missing information. 238 patients were included in the final analysis. 48 (20.2%) patients had positive culture for gram-negative organisms after onset of CDI. Urine was the most common source for gram-negative organisms (39/48, 81.3%) followed by blood (8/48,16.7%). The most common isolated gram-negative organisms were Escherichia coli (18/48, 37.5%) and Klebsiella pneumonia (9/48, 18.8%). The most common CDI treatment regimens were metronidazole monotherapy (137/238, 57.6%), vancomycin monotherapy (13/238, 5.5%), and combination therapy (88/238, 37.0%). Among patients who were treated with metronidazole monotherapy, vancomycin monotherapy, and combination therapy, 30(30/137, 21.9%), 3 (3/13,23.1%), and 15 (15/88, 17.1%) had positive culture for gram-negative organisms, respectively (P= 0.6). Ninety-seven (97/238,40.8%) patients had severe CDI, 40 (40/97, 41.2%) were treated with metronidazole monotherapy, 5(5/97, 5.2%) with vancomycin monotherapy, and 52 (52/97, 53.6%) with combination therapy. 26 (26/141,18.4%) and 22 (22/97, 22.7%) had positive culture for gram-negative organisms among patients with non-severe and severe CDI, receptively (P= 0.7). In the multivariate analysis, neither type of CDI treatment regimen (P=0.2, 95% CI 0.30–1.31) nor CDI severity (P=0.4, 95% CI 0.67–2.69) was associated an increased risk of infection with gram-negative organisms after CDI onset. Conclusions Contrary to the reported literature, we did not find that oral vancomycin-based CDI treatment was associated with increased risk of infection with gram-negative organisms. Funding Agencies None
Editorial: Corticosteroids for severe checkpoint inhibitor‐induced liver injury—Not one size fits all?

Morven Cunningham

DOI: https://doi.org/10.1111/apt.17911

IF: 9.524

2024-03-12

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 7, Page 905-906, April 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis

Ayesha Shah,Michael P. Jones,Gavin Callaghan,Thomas Fairlie,Xiaomin Ma,Emma L. Culver,Katherine Stuart,Peter De Cruz,James O’Beirne,James H. Tabibian,Axel Dignass,Ali Canbay,Gregory J. Gores,Gerald J. Holtmann

DOI: https://doi.org/10.1097/hc9.0000000000000347

2024-01-01

Hepatology Communications

Abstract:Background: Primary sclerosing cholangitis (PSC) is an immune-mediated, chronic cholestatic liver disease. Currently, liver transplantation is the only established life-saving treatment. Several studies have evaluated the effect of different biologic therapies on PSC with inconclusive findings. We conducted a systematic review and meta-analysis to assess the effects of biologics in PSC and associated inflammatory bowel disease (IBD). Methods: MEDLINE, Scopus, and Embase were searched up to July 31, 2023, for studies reporting the effects of biologics in patients with PSC-IBD. Effects of biologic therapy on alkaline phosphatase, total bilirubin, ulcerative colitis response score, and adverse events were calculated and expressed as standardized difference of means (SMD), proportions, and 95% CI using a random-effects model. Results: Six studies, including 411 PSC-IBD patients who received biologics, were included. Biologic treatment was associated with no change in alkaline phosphatase (SMD: 0.1, 95% CI: −0.07 −0.17, p =0.43), but a small and statistically significant increase in total bilirubin (SMD: 0.2, 95% CI: 0.05–0.35, p <0.01). 31.2% (95% CI: 23.8–39.7) of patients with IBD achieved endoscopic response, and there was a significant improvement in ulcerative colitis response score (SMD: −0.6,95% CI: −0.88 to 0.36, p <0.01). Furthermore, 17.6% (95% CI: 13.0–23.5) of patients experienced adverse events severe enough to discontinue therapy, and 29.9% (95% CI: 25.2–34.8) had a loss of response to biologics. Conclusions: Treatment of patients with PSC-IBD with biologics (vedolizumab, infliximab, and adalimumab) was not associated with improvement of biochemical markers of cholestasis. Biologics are effective in treating the colitis associated with PSC. Vedolizumab was associated with worsening liver enzymes in contrast to other biologics, a finding that warrants further study.

gastroenterology & hepatology
Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis

Dominik Bettinger,Robert Thimme,Lukas Sturm

DOI: https://doi.org/10.1111/apt.17928

IF: 9.524

2024-04-25

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 10, Page 1282-1283, May 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Evaluation of Rectal Vancomycin Irrigation for Treatment of Clostridioides difficile Infection in Patients Post-Colectomy for Toxic Colitis

Megan E Feeney,Molly Thompson,Anthony T Gerlach,Amy Rushing,David C Evans,Daniel S Eiferman,Claire V Murphy

DOI: https://doi.org/10.1089/sur.2018.265

Abstract:Background: Clostridioides difficile infection (CDI) accounts for as many as 25% of episodes of antibiotic-associated diarrhea and is the most common cause of healthcare-associated diarrhea. Rectal vancomycin irrigation is a therapy option; however, evidence is limited for its value post-colectomy. The objective of this study was to describe outcomes of patients who underwent total colectomy for fulminant C. difficile colitis and received rectal vancomycin post-operatively. Methods: This was a single-center retrospective chart review of adult patients who underwent total colectomy for fulminant CDI. Efficacy outcomes were all-cause in-hospital death, intensive care unit (ICU) and hospital length of stay, ventilator-free days at day 28 post-procedure, development of proctitis or pseudomembranes, need for re-initiation of CDI therapy, and normalization of infectious signs and symptoms at completion of CDI therapy. The primary safety outcome was the incidence of rectal stump blowout. Results: Of the 50 patients included, 38 (76%) received treatment with rectal vancomycin at the discretion of the surgeon. The Sequential Organ Failure Assessment score on the day of the procedure was higher in the rectal vancomycin group; however, this difference did not reach statistical significance. No difference was observed between the groups in the primary outcome of all-cause death. There was no significant difference between the groups for hospital length of stay, but there was a trend toward longer ICU length of stay for patients who received rectal vancomycin (9.5 days vs. 2.5 days; p = 0.05). No differences in the remaining secondary efficacy outcomes were observed. No episodes of rectal stump blowout were observed in either group. Conclusions: This study aimed to add to the limited data on the use of rectal vancomycin irrigation post-colectomy for toxic C. difficile colitis. Although our results do not support routine use of rectal vancomycin irrigation, they suggest that this therapy is not harmful if providers are considering its use for severe infections refractory to alternative treatment.
Intracolonic Administration of Vancomycin in Intensive Care Unit Patients with Severe Clostridium Difficile Colitis

Alex Teixeira,Kartikeya Tripathi,Yesenia Greeff,Omar Sorour,Paul Mccallion,Garrison Davis,Khaled Sorour

DOI: https://doi.org/10.7759/cureus.11573

2020-11-19

Cureus

Abstract:Background: Clostridium difficile infection (CDI) is a major cause of antibiotic-associated diarrhea worldwide. The incidence of sepsis has been shown to be increasing due to severe or fulminant colitis. Oral vancomycin is the treatment of choice for CDI, but it is often ineffective in patients in the intensive care unit (ICU) due to poor intestinal motility. We present a review of eight cases with severe to fulminant CDI treated with adjunctive intracolonic vancomycin (ICV) administration. Methods: A retrospective chart review identified patients in sepsis with severe colitis and positive Clostridium difficile toxin A or B. Patients who had failed standard therapy for CDI were given adjunctive ICV through an enteric tube, which was inserted via colonoscopy. To indicate the severity of patients, the patients selected had required vasopressor support. Results: Eight patients (37.5% females) received this adjunctive treatment; the mean age was 73.25. The average Acute Physiology and Chronic Health Evaluation (APACHE) 2 score at the time of the procedure was 39. The median length of stay was 5.5 days, with in-hospital mortality of 37.5% and an average time to death of 1.33 days from the day of colonoscopy. Conclusion: Colonoscopic decompression and administration of vancomycin for fulminant CDI using an enteric tube can have favorable outcomes in severely ill patients whose surgical options carry a high risk of mortality. Further larger randomized controlled trials are needed to evaluate its efficacy.
Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis

Brigid Pinnuck,Kate D. Lynch

DOI: https://doi.org/10.1080/14656566.2024.2407022

2024-10-13

Expert Opinion on Pharmacotherapy

Abstract:Introduction Primary sclerosing cholangitis (PSC) is the most specific hepatobiliary extraintestinal manifestation in inflammatory bowel disease (IBD). PSC ultimately has a poor prognosis, with disease progression resulting in liver cirrhosis and subsequent liver failure. While there is current data for the medical management of IBD, the optimal approach for concurrent PSC-IBD is unclear.

pharmacology & pharmacy
Review article: Prevention of inflammatory bowel disease—The path forward

Sérgio Bronze,Manasi Agrawal,Jean‐Frédéric Colombel,Joana Torres,Ryan C. Ungaro

DOI: https://doi.org/10.1111/apt.18263

IF: 9.524

2024-10-16

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 60, Issue 9, Page 1166-1175, November 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Impact of oral vancomycin treatment duration on rate of Clostridioides difficile recurrence in patients requiring concurrent systemic antibiotics

Diana Kwiatkowski,Kassandra Marsh,Alyson Katz,John Papadopoulos,Jonathan So,Vincent J. Major,Philip M. Sommer,Sarah Hochman,Yanina Dubrovskaya,Serena Arnouk

DOI: https://doi.org/10.1017/ice.2024.4

2024-01-31

Infection Control and Hospital Epidemiology

Abstract:Background: There is a paucity of data guiding treatment duration of oral vancomycin for Clostridiodes difficile infection (CDI) in patients requiring concomitant systemic antibiotics. Objectives: To evaluate prescribing practices of vancomycin for CDI in patients that required concurrent systemic antibiotics and to determine whether a prolonged duration of vancomycin (>14 days), compared to a standard duration (10–14 days), decreased CDI recurrence. Methods: In this retrospective cohort study, we evaluated adult hospitalized patients with an initial episode of CDI who were treated with vancomycin and who received overlapping systemic antibiotics for >72 hours. Outcomes of interest included CDI recurrence and isolation of vancomycin-resistant Enterococcus (VRE). Results: Among the 218 patients included, 36% received a standard duration and 64% received a prolonged duration of treatment for a median of 13 days (11–14) and 20 days (16–26), respectively. Patients who received a prolonged duration had a longer median duration of systemic antibiotic overlap with vancomycin (11 vs 8 days; P < .001) and significantly more carbapenem use and infectious disease consultation. Recurrence at 8 weeks (12% standard duration vs 8% prolonged duration; P = .367), recurrence at 6 months (15% standard duration vs 10% prolonged duration; P = .240), and VRE isolation (3% standard duration vs 9% prolonged duration; P = .083) were not significantly different between groups. Discontinuation of vancomycin prior to completion of antibiotics was an independent predictor of 8-week recurrence on multivariable logistic regression (OR, 4.8; 95% CI, 1.3–18.1). Conclusions: Oral vancomycin prescribing relative to the systemic antibiotic end date may affect CDI recurrence to a greater extent than total vancomycin duration alone. Further studies are needed to confirm these findings.

infectious diseases,public, environmental & occupational health
Gut Microbiota in Primary Sclerosing Cholangitis: From Prognostic Role to Therapeutic Implications

Valeria Maccauro,Francesca Fianchi,Antonio Gasbarrini,Francesca Romana Ponziani

DOI: https://doi.org/10.1159/000538493

2024-03-25

Digestive Diseases

Abstract:Background: Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease of unknown etiology characterized by biliary inflammation and periductal fibrosis. The gut microbiota plays a crucial role in the pathogenesis of PSC by regulating bile acid metabolism, inflammation, and immune response. On the other hand, liver disease progression affects the composition of the gut microbiota, fostering these mechanisms in a mutual detrimental way. Summary: Recent evidences described a specific pro-inflammatory microbial signature in PSC patients, with an overall reduced bacterial diversity and the loss of beneficial metabolites such as short-chain fatty acids. As effective therapies for PSC are still lacking, targeting the gut microbiota offers a new perspective in the management of this disease. To date, antibiotics, fecal microbiota transplantation, and probiotics are the most studied gut microbiota-targeted intervention in PSC, but new potential strategies such as vaccines and bacteriophages represent possible future therapeutic horizons. Key Messages: In this review, we focus on the role of the gut microbiota in PSC, considering its pathogenetic and prognostic role and the therapeutic implications.

gastroenterology & hepatology
Oral Vancomycin May Be Associated with Earlier Symptom Resolution Than Metronidazole for Hospitalized Children with Nonsevere Clostridioides Difficile Infections

Jianyi Yin,Larry K. Kociolek,Rebecca G. Same,Alice J. Hsu,Joe Amoah,Pranita D. Tamma

DOI: https://doi.org/10.1093/ofid/ofz492

2019-01-01

Open Forum Infectious Diseases

Abstract:Abstract Objective National guidelines recommend oral vancomycin over oral metronidazole as first-line treatment for nonsevere Clostridioides difficile infection (CDI) in adults. Guidelines recommend metronidazole for children with nonsevere CDI, emphasizing that comparative effectiveness studies comparing the relative efficacy of vancomycin and metronidazole are lacking in children. Method We conducted an observational study of hospitalized children with nonsevere CDI treated with metronidazole versus vancomycin using an inverse probability of treatment-weighted propensity-score analysis. All of the following criteria had to be present for children with positive CDI testing for study eligibility: (1) ≥3 new-onset unformed stools within a 24-hour period; (2) 2–17 years of age; (3) hospitalization for ≥48 hours for CDI; (4) no laxative use ≤48 hours; (5) no alternate etiology for diarrhea; (6) no previous episode of CDI ≤3 months; (7) no concurrent non-CDI–targeted antibiotic therapy, and (8) no severe or fulminant CDI. Results One hundred ninety-two patients met eligibility criteria; 141 (73.4%) received oral metronidazole and 51 (26.6%) children received oral vancomycin. Baseline characteristics were similar between the 2 groups in the weighted cohort. Of 141 patients, 101 (71.7%) children receiving metronidazole had clinical improvement by day 5, whereas 44 of 51 (86.3%) cases resolved with vancomycin (odds ratio, 0.40; 95% confidence interval, 0.17–0.97; P = .04). The odds of CDI recurrence within 12 weeks were similar between the groups. Conclusions Our study suggests that children with nonsevere CDI have earlier resolution of clinical symptoms when prescribed vancomycin compared with metronidazole. Large interventional studies are necessary to evaluate the reproducibility of our findings.
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease

Elsa L. S. A. Liere,Nanne K. H. Boer,Elsa L. S. A. van Liere,Nanne K. H. de Boer

DOI: https://doi.org/10.1111/apt.17876

IF: 9.524

2024-02-26

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 6, Page 792-793, March 2024.

pharmacology & pharmacy,gastroenterology & hepatology
P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series

T Holvoet,B Verstockt,M Lenfant,M Julsgaard,D Drobne,A Thakor,H Gordon,T Molnar,E V Savarino,D G Ribaldone,P Miheller,S Vieujean,I Candel,L Menchen,D Bettenworth,P Eder,A Issachar,T Lobaton

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0751

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease often necessitating liver transplantation (LTX). Approximately 70% of PSC patients have a concomitant diagnosis of inflammatory bowel disease (IBD) and could need treatment with biological therapy on top of the immunosuppression to prevent transplant rejection. Vedolizumab (VDZ) and ustekinumab (UST), both agents with a favorable safety profile, are often used in this population despite lack of data concerning safety and effectiveness in the post-LTX setting. Methods A retrospective multicenter case series was performed as a part of the European Crohn's and Colitis Organisation [ECCO] Collaborative Network of Exceptionally Rare case reports [CONFER] project. Primary endpoints were clinical and endoscopic remission at week 52, occurrence of infectious complications, occurrence of malignancy, hospitalizations, and death after liver transplantation. Results In this retrospective study, 58 patients (male n= 34 (59%), median age 42 (interquartile range (IQR) 32-52) were included across 16 participating centers of which 24 (38%) were treated with UST and 40 (63%) with VDZ. Twelve patients (20%) were diagnosed with Crohn’s disease (CD), 44 (76%) with ulcerative colitis (UC), 2 (3%)- with unclassified IBD (IBD-U) and in 12 (20%) patients had an ileal pouch anal anastomosis (IPAA). Median disease duration was 16 years (IQR 13-26) and 33 (56%) had received biological therapy prior to LTX (33% anti-TNF, 11% VDZ, 5% UST). Median disease duration for PSC was 15.5 years (IQR 11-25) and median time since LTX was 6 years (IQR 4-10). Clinical remission, assessed according to physician global assessment, at week 52 was achieved in 44% of VDZ compared to 38% of UST treated patients (p=0.17), while endoscopic remission was seen in 17% of patients in the VDZ group versus 33% in the UST treated patients (p=0.87). Clinical effectiveness was similar across CD (respectively 33% and 20%), UC (33% and 37%) and IPAA patients (36% vs 60%). Infectious complications occurred in 21 patients (29%; 27% VDZ vs 33% UST) post LTX on biological therapy (p=0.66), malignancy occurred in 10 patients (14.1%, 12.8% VDZ vs 16.7% UST, p=0.66), hospitalizations in 32 (45%; 51% VDZ vs 34% UST, p=0.15), and death in 2 patients (3.4%; 2.1% VDZ vs 4.2% UST, p=0.66) (see table). Conclusion In IBD-PSC patients who underwent LTX both UST and VDZ show similar effectiveness with clinical remission rates of respectively 44% and 38% after 1 year. Safety profiles are similar although infectious complications and occurrence of malignancy remains an important concern in this patient group.

gastroenterology & hepatology
Evaluation of Sequential Oral Versus Intravenous Antibiotic Treatment of Enterococcus faecalis Bloodstream Infections

Carly Loudermilk,Joshua Eudy,Stephanie Albrecht,Cara N. Slaton,Stefanie Stramel,Patrick Tu,Benjamin Albrecht,Sarah B. Green,Jeannette L. Bouchard,Alison I. Orvin,Christian F. Caveness,Andrea Sikora Newsome,Christopher M. Bland,Daniel T. Anderson

DOI: https://doi.org/10.1177/10600280241260146

IF: 3.4628

2024-06-20

Annals of Pharmacotherapy

Abstract:Annals of Pharmacotherapy, Ahead of Print. Background:Intravenous (IV) antibiotics have historically been considered standard of care for treatment of bloodstream infections (BSIs). Recent literature has shown sequential oral (PO) therapy to be noninferior to IV antibiotics for certain pathogens and disease states. However, a gap exists in the literature for BSI caused by Enterococcus faecalis.Objective:To compare outcomes of definitive sequential PO therapy to definitive IV therapy in patients with E faecalis BSI.Methods:Multicenter, retrospective, matched cohort study of adult patients with at least one blood culture positive for E faecalis from January 2017 to November 2022. Patients with polymicrobial BSI, concomitant infections requiring prolonged IV antibiotic therapy, those who did not receive antibiotic therapy, and those who died within 72 hours of index culture were excluded. Subjects were matched based on source of infection in a 2:1 (IV:PO) ratio. The primary outcome was a composite of all-cause mortality and treatment failure. Secondary outcomes included hospital length of stay (LOS), antibiotic duration, and 30-day readmission rate.Results:Of the 186 patients who met criteria for inclusion, there was no statistically significant difference in the primary composite outcome for PO compared to IV therapy (14.5% vs 21.8%; OR 0.53 [0.23-1.25]) or 30-day readmission (17.5% vs 29%; OR 0.53 [0.25-1.13]). Hospital LOS was significantly longer in patients receiving IV-only therapy (6 days vs 14 days; P < 0.001).Conclusion and Relevance:Sequential oral therapy for E faecalis BSI had similar outcomes compared to IV-only treatment and may be considered in eligible patients.

pharmacology & pharmacy
Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models

Nihal Hasan,Hongyi Yang

DOI: https://doi.org/10.1371/journal.pone.0285613

IF: 3.7

2023-05-11

PLoS ONE

Abstract:Background: Despite the number of available therapies for ulcerative colitis (UC), severe side effects and high cost has limited their clinical application. Thus, finding new alternative strategies with minimal side effects is inevitable. Therefore, this study aimed to compare the effectiveness of different therapeutic approaches in DSS-induced colitis. Methods: Firstly, we designed oral bio-therapeutic products, Live Bacterial Products (LBP), which include a mixture of fecal bacteria strains isolated from healthy mice and prepared by microencapsulation and freeze-dried techniques. Then we investigated the efficiency of 7 days of freeze-dried FMT, LBP, and vancomycin treatments in DSS-induced colitis. Secondly, we compared the effect of 15 days of microbial therapies (freeze-dried powder of FMT and LBP microcapsules) and seven days of oral vancomycin on the severity of colitis in mice. Furthermore, the levels of IL-1β and TNF-α were measured in serum by ELISA, and the fecal microbiota diversity was analyzed by high-throughput sequencing for all mice groups. Results: After seven days of treatments, our results indicated that oral vancomycin reduced the severity of DSS-induced colitis in mice, where weight gain and a decrease in IL-1 β and TNF-α levels were observed in the vancomycin group compared with other treatment groups. While after two weeks of treatment, the LBP microcapsules were able to reduce the severity of colitis. And at the end of the treatment period, weight gain and a decrease in the DAI scores and the levels of IL-1β and TNF-α were noted in the LBP treatment group compared to other treatment groups. By high-throughput sequencing of the 16S rRNA gene, our results showed that while the microcapsules LBP treatment increased the fecal microbial diversity, after vancomycin therapy, most of the fecal microbiota genera and operational taxonomic units (OTUs) were depleted. Conclusion: Our results concluded that treatment duration and preparation methods affect the microbial therapies' efficiency in UC. Furthermore, this study highlighted the negative consequences of oral vancomycin administration on gut health that should be known before using this medication.
Letter: Thioguanine, an underutilised option in inflammatory bowel disease?

John D. Chetwood,Sudarshan Paramsothy,Rupert W. Leong

DOI: https://doi.org/10.1111/apt.17920

IF: 9.524

2024-03-25

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 8, Page 1009-1010, April 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Editorial: Advancing care in Crohn's disease—Time to standardise bowel preparation scales

Mohammad Shehab,Talat Bessissow

DOI: https://doi.org/10.1111/apt.18269

IF: 9.524

2024-09-20

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Solitano et al papers. To view these articles, visit https://doi.org/10.1111/apt.18210 and https://doi.org/10.1111/apt.18288

pharmacology & pharmacy,gastroenterology & hepatology

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?

An 'Adaptive Treatment Strategy' for Oral Vancomycin in Patients with the Orphan Disease Primary Sclerosing Cholangitis

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon

A100 ORAL VANCOMYCIN THERAPY FOR CLOSTRIDIOIDES DIFFICILE INFECTION AND RISK OF INFECTION WITH GRAM-NEGATIVE ORGANISMS

Editorial: Corticosteroids for severe checkpoint inhibitor‐induced liver injury—Not one size fits all?

Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis

Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis

Evaluation of Rectal Vancomycin Irrigation for Treatment of Clostridioides difficile Infection in Patients Post-Colectomy for Toxic Colitis

Intracolonic Administration of Vancomycin in Intensive Care Unit Patients with Severe Clostridium Difficile Colitis

Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis

Review article: Prevention of inflammatory bowel disease—The path forward

Impact of oral vancomycin treatment duration on rate of Clostridioides difficile recurrence in patients requiring concurrent systemic antibiotics

Gut Microbiota in Primary Sclerosing Cholangitis: From Prognostic Role to Therapeutic Implications

Oral Vancomycin May Be Associated with Earlier Symptom Resolution Than Metronidazole for Hospitalized Children with Nonsevere Clostridioides Difficile Infections

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease

P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series

Evaluation of Sequential Oral Versus Intravenous Antibiotic Treatment of Enterococcus faecalis Bloodstream Infections

Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models

Letter: Thioguanine, an underutilised option in inflammatory bowel disease?

Editorial: Advancing care in Crohn's disease—Time to standardise bowel preparation scales